What is the mechanism of action of Teclistamab?

Teritumumab(Teclistamab) is a bispecific T cell-binding antibody that binds to TCD3< expressed on the surface of T cells. The receptor binds to multiple myeloma cells and the B cell maturation antigen (BCMA) expressed on the surface of some healthy B cells. In vitro, Teritusumab(activates T cells, causing the release of various pro-inflammatory cytokines and leading to the lysis of multiple myeloma cells. When administered subcutaneously, the average bioavailability of Teritusumab is 72%. Median (Range)TMaximumteritusumabThe first and 13Thailand(Thailand) therapeutic doses were 139 respectively (19 to 168) hours and 72 (24 to 168) hours. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about overseas high-quality drugs for you.